Med. Pro Praxi 2008; 5(1): 33-38

Obsedantně kompulzivní porucha a její léčba

doc. MUDr. Ján Praško CSc, MUDr. Hana Prašková, MUDr. Michal Raszka, PhDr. Jana Kopřivová
Psychiatrické centrum Praha, 3. LF UK, Praha

Obsedantně kompulzivní porucha je častá, chronická a handicapující porucha charakterizovaná obsesemi a kompulzemi. Obsese jsou rekurentní, nutkavé a stresující myšlenky, představy nebo impulzy, zatímco kompulze jsou opakované, zdánlivé nesmyslné projevy chování, ke kterým se postižený cítí být nutkán. Obsese a kompulze způsobují značný distres, zabírají hodně času a narušují významně běžný život, sociální i pracovní aktivity. Moderní přístupy v léčbě, speciálně kognitivně behaviorální terapie a serotonergní léky mohou významně pomoci ke snížení příznaků. Používání SSRI a clomipraminu je unikátní tím, že jsou to jediné léky s výrazným serotonergním účinkem, které jsou u OCD efektivní.

Keywords: obsedantně kompulzivní porucha, KBT, SSRI, clomipramin

Published: March 27, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Praško J, Prašková H, Raszka M, Kopřivová J. Obsedantně kompulzivní porucha a její léčba. Med. praxi. 2008;5(1):33-38.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Abrahamowitz JS. Effectiveness of psychological and pharmacological treatments for obsessive-compulsive disorder: a quantitative review. J Consult Clin Psychol 1997; 65: 44-52. Go to original source... Go to PubMed...
    2. Albert U, Bergesio C, Pessina E. Management of treatment resistant obsessive - compulsive disorder. Algorithms for pharmacotherapy. Panminerva Medica 2002; 44: 83-91.
    3. Arnold LM, Auchenbach MB, McElroy SL. Psychogenic excoriation. Clinical features, proposed diagnostic criteria, epidemiology and approaches to treatment. CNS Drugs 2001; 15(5): 351-359. Go to original source... Go to PubMed...
    4. Atmaca M, Kuoglu M, Tezcan E, Gecici O: Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study. Int Clin Psychopharmacology 2002; 17: 115-119. Go to original source... Go to PubMed...
    5. Baer L, Rauch SL, Ballentine T et al. Cingulotomy for untreatable obsessive-compulsive disorder. Arch Gen Psychiatry 1995; 52: 384-392. Go to original source... Go to PubMed...
    6. Berthier ML, Kulisevsky J, Gironell A, Heras JA. Obsessive-compulsive disorder associated with brain lesions: clinical phenomenology, cognitive function, and anatomic correlates. Neurology. 1996; 47(2): 353-361. Erratum in: Neurology 1996; 47(3): 855. Go to original source... Go to PubMed...
    7. Bland RC, Newman SC, Orn H. Epidemiology of psychiatric disorders in Edmonton. Acta Psychiatrica Scandinavica 1988; 77(Suppl.): 338. Go to original source... Go to PubMed...
    8. Bogetto F, Bellino S, Vaschetto P, Ziero S. Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): A 12-week open trial. Psychiatry Research 2000 OCT 30; 96/2: 91-98. Go to original source... Go to PubMed...
    9. Calikusu C, Yucel B, Polat A, Baykal C. The relationship between psychogenic excoriation and psychiatric disorders: a comparative study. Turk Psikiyatri Derg. 2002 Winter; 13(4): 282-289. Go to PubMed...
    10. Clomipramine Collaborative Study Group. Clomipramine in the treatment of patients with obsessive-compulsive disorder. Arch Gen Psychiatry 1991; 48: 730-738. Go to original source... Go to PubMed...
    11. Cosoff S, Hafner RJ. The prevalence of comorbid anxiety in schizophrenia, schizoaffective disorder, and bipolar disorder, Austral N Zealand J Psychiatry 1998; 32: 67-72. Go to original source... Go to PubMed...
    12. Crockett BA, Davidson JRT, Churchill LE. Treatment of obsessive-compulsive disorder with clonazepam and sertraline versus placebo plus sertraline. Poster presented at the 39th annual meeting of New Clinical Drug Evaluation Unit, Boca Raton, FL, June 1, 1999.
    13. Cucker A, State MW, King RA, Davis N, Ward DC. Candidate locus for Gilles de la Tourette syndrome/obsessive compulsive disorder/chronic tic disorder at 18q22. Am J Med Genet A. 2004; 130(1): 37-39. Go to original source... Go to PubMed...
    14. Davidson JTR, Connor KM. Treatment of anxiety disorders. In: Schatzberg AF a Nemeroff CB (eds): Textbook of psychopharmacology. American Psychiatric Press, Washington 2004; 913-934.
    15. Demet MM, Deveci A, Taskin EO, Ermertcan AT, Yurtsever F, Deniz F, Bayraktar D, Ozturkcan S. Obsessive-compulsive disorder in a dermatology outpatient clinic. Gen Hosp Psychiatry. 2005; 27(6): 426-430. Go to original source... Go to PubMed...
    16. Eisen JL, Goodman WK, Keller MB. Patterns of remission and relapse in obsessive-compulsive disorder: a two-year prospective study. J Clin Psychiatry 1999; 60: 346-351. Go to original source... Go to PubMed...
    17. Emmelkamp PMG. Phobic and obsessive-compulsive disorders. New York: Plenum, 1982. Go to original source...
    18. Fisman SN, Walsh L. Obsessive-compulsive disorder and fear of AIDS contamination in childhood. J Am Acad Child Adolesc Psychiatry 1994; 33(3): 349-353. Go to original source... Go to PubMed...
    19. Foa EB a Steketee GS. Obsessive-compulsives: conceptual issues and treatment interventions. In: Hersen RM (ed): Progress in behaviour modification. Academic Press, New York 1979; 1-53. Go to original source...
    20. Goodman WK, McDougle CJ, Barr LC. Biological approaches to treatment-resistant OCD. J Clin Psychiatry 1993; 54: 16-26.
    21. Greist JH, Chouinard G, Duboff ET. Double - blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. Arch Gen Psychiatry 1995; 52: 289-296. Go to original source... Go to PubMed...
    22. Greist JH, Jenike M, Robinson D et al. Efficacy of fluvoxamine in obsessive-compulsive disorder: results of a multi-center, double-blind, placebo-controlled trial. European J Clin Res 1995; 7: 195-204.
    23. Greist JH, Jefferson JW. Pharmacotherapy for obsessive-compulsive disorder. Br J Psychiatry 1998; 173(suppl 35): 64-70. Go to original source...
    24. Gupta MA, Guptat AK. The use of antidepressant drugs in dermatology. J Eur Acad Dermatol Venereol 2001; 15(6): 512-518. Go to original source... Go to PubMed...
    25. Jenike M, Baer L, Ballantine HL et al. Cingulotomy for refractory obsessive-compulsive disorder: a long-term follow up of 33 pacients. Arch Gen Psychiatry 1991; 48: 548-555. Go to original source... Go to PubMed...
    26. Johannes S, Wieringa BM, Nager W, Rada D, Muller-Vahl KR, Emrich HM, Dengler R, Munte TF, Dietrich D. Tourette syndrome and obsessive-compulsive disorder: Event-related brain potentials show similar mechanisms of frontal inhibition but dissimilar target evaluation processes. Behavioural Neurology 2003; 14/1-2: 9-17. Go to original source... Go to PubMed...
    27. Jung HH, Kim CH, Chang JH, Park YG, Chung SS, Chang JW. Bilateral anterior cingulotomy for refractory obsessive-compulsive disorder: Long-term follow-up results. Stereotact Funct Neurosurg. 2006; 84(4): 184-189. Epub 2006 Aug 14. Go to original source... Go to PubMed...
    28. Kant R, Smith-Seemiller L, Duffy JD. Obsessive-compulsive disorder after closed head injury: review of literature and report of four cases. Brain Injury 1996; 10: 55-63. Go to original source... Go to PubMed...
    29. Kaplan A, Hollander E. A review of pharmacologic treatments for obsessive - compulsive disorder. Psychiatric Services 2003; 54(8): 1111-1118. Go to original source... Go to PubMed...
    30. Kalra H, Tandon R, Trivedi JK, Janca A. Pregnancy-induced obsessive compulsive disorder: a case report. Ann Gen Psychiatry. 2005; 4(1): 12. Go to original source... Go to PubMed...
    31. Karno M, Golding JM, Sorenson SB. The epidemiology of obsessive - compulsive disorder in five US-comunities. Arch Gen Psychiatry 1988; 45: 1094-1099. Go to original source... Go to PubMed...
    32. Karno M, Golding JM. Obsessive compulsive disorder. In: Robins JM, Reiger DA, eds. Psychiatric disorders in America. Epidemiologic catchment area study. New York: Free Press, 1991.
    33. Koran LM, Sallee FR, Pallanti S et al. Rapid benefit of intravenous pulse loading clomipramine for obsessive-compulsive disorder: a double-blind comparison. Am J Psychiatry 1997; 154: 396-401. Go to original source... Go to PubMed...
    34. Koran LM, Ringold AL, Elliot MA. Olanzapine augmentation for treatment-resistent obsessive-compulsive disorder. J Clin Psychiatry 2000; 61: 514-517. Go to original source... Go to PubMed...
    35. Kosová J, Pašková B. In: Seifertová H, Praško J, Hoschl C. Postupy v léčbě psychických poruch. Ac. Med. Prag. 2004: 234-251.
    36. Kruger S, Cooke RG, Hasey GM. Comorbidity of obsessive-compulsive disorder in bipolar disorder. J Affect Disorders 1995; 34: 117-120. Go to original source... Go to PubMed...
    37. Laplane D, Boulliat J, Baron JC, Pillon B, Baulac M. Obsessive-compulsive behavior caused by bilateral lesions of the lenticular nuclei. A new case. Encephale. 1988; 14(1): 27-32. Go to PubMed...
    38. Laplane D, Levasseur M, Pillon B, Dubois B, Baulac M, Mazoyer B a kol. Obsessive-compulsive and other behavioural changes with bilateral basal ganglia lesions. Brain J Neuro 1989; 112: 699-725. Go to original source... Go to PubMed...
    39. Leonard H, Swedo S, Coffey M a kol. Clomipramine vs desipramine in childhood obsessivecompulsive disorder. Psychopharmacol Bull 1988; 24: 43-45. Go to PubMed...
    40. Leonard H, Swedo SE, Koby E, Rapoport JL, Lenane MC, Cheslow D, Hamburger S. Treatment of obsessive-compulsive disorder with clomipramine and desmethylimipramine in children and adolescents: A double-blind crossover comparison. Arch Gen Psychiatry 1989; 46: 1088-1092. Go to original source... Go to PubMed...
    41. Limosin F, Ades J. Psychiatric and psychological aspects of premenstrual syndrome. Encephale 2001; 27(6): 501-508. Go to PubMed...
    42. March JS, Leonard HL. obsessive-compulsive disorder in children and adolescents: a review of the past 10 years. J Am Acad Child Adolesc Psychiatry 1996; 35(10): 1265-1273. Go to original source... Go to PubMed...
    43. Marks IM. Fears, phobias and rituals. Oxford University Press, New York; 1987.
    44. Marks IM, Stern RS, Mawson D, Cobb J, McDonald R. Clomipramine and exposure for obsessive-compulsive rituals: I. Br J Psychiatry 1980; 136: 1-25. Go to original source... Go to PubMed...
    45. Marks I. Behaviour therapy for obsessive-compulsive disorder: A decade of progress. Can J Psychiatry 1997; 42: 1021-1027. Go to original source... Go to PubMed...
    46. McDougle CJ, Goodmann WK, Leecman JF. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. Arch Gen Psychiatry 1994; 51: 302-308. Go to original source... Go to PubMed...
    47. McDougle CJ, Epperson CN, Pelton GH, Wasylink S, Price LH. A double-blind, placebo-controlled study of risperidone addition in serotonine reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry 2000; 57: 794-801. Go to original source... Go to PubMed...
    48. Miguel EC, Baer L, Coffey BJ, Rauch SL, Savage CR, O' Sullivan RL, Phillips K, Moretti C, Leckman JF, Jenike MA. Phenomenological differences appearing with repetitive behaviours in obsessive-compulsive disorder and Gilles de la Tourette' s syndrome. Br J Psychiatry. 1997; 170: 140-145. Go to original source... Go to PubMed...
    49. Mohr N, Vythilingum B, Emsley RA, Stein DJ. Quetiapine augmentation of serotonin reuptake inhibitors in obsessive-compulsive disorder. Int Clin Psychopharmacology 2002; 17: 37-40. Go to original source... Go to PubMed...
    50. Murphy TK, Sajid MW, Goodman WK. Immunology of obsessive-compulsive disorder. Psychiatr Clin North Am 2006; 29(2): 445-469. Go to original source... Go to PubMed...

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.